Organ-on-.chip; Autoimmune diseases; Omics technologies.

By cytomics and vesicolomics, we are developing high-throughput biomedical assays capable of generating vast amounts of patient-specific data, with the aim to uncover early biomarkers of immune-mediated diseases and provide new insights into their pathophysiologic mechanisms.

In addition to multi-omics techniques, we harness the power of organ-on-chip technology to recreate the microenvironment of human organs, providing a platform for studying disease mechanisms and drug responses with unprecedented fidelity, enabling more accurate and personalized medicine, with the ultimate goal of improving patient outcomes.